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Simple Summary: Targeted monotherapies are ineffective in the treatment of brain metastasis of
ERBB2+ breast cancer (BC) underscoring the need for combination therapies. The lack of robust
preclinical models has further hampered the assessment of treatment modalities. We report here a
clinically relevant orthotopic mouse model of ERBB2+ BC that spontaneously metastasizes to brain
and demonstrates that targeting the c-MET/ERBB1 axis with a combination of cabozantinib and
neratinib decreases primary tumor growth and prevents brain metastasis in ERBB2+ BC.
Abstract: Brain metastasis (BrM) remains a significant cause of cancer-related mortality in epidermal
growth factor receptor 2-positive (ERBB2+ ) breast cancer (BC) patients. We proposed here that a
combination treatment of irreversible tyrosine kinase inhibitor neratinib (NER) and the c-MET inhibitor
cabozantinib (CBZ) could prevent brain metastasis. To address this, we first tested the combination
treatment of NER and CBZ in the brain-seeking ERBB2+ cell lines SKBrM3 and JIMT-1-BR3, and in
ERBB2+ organoids that expressed the c-MET/ERBB1 axis. Next, we developed and characterized
an orthotopic mouse model of spontaneous BrM and evaluated the therapeutic effect of CBZ and
NER in vivo. The combination treatment of NER and CBZ significantly inhibited proliferation
and migration in ERBB2+ cell lines and reduced the organoid growth in vitro. Mechanistically,
the combination treatment of NER and CBZ substantially inhibited ERK activation downstream of the
c-MET/ERBB1 axis. Orthotopically implanted SKBrM3+ cells formed primary tumor in the mammary
fat pad and spontaneously metastasized to the brain and other distant organs. Combination treatment
with NER and CBZ inhibited primary tumor growth and predominantly prevented BrM. In conclusion,
the orthotopic model of spontaneous BrM is clinically relevant, and the combination therapy of NER
and CBZ might be a useful approach to prevent BrM in BC.
Keywords: breast cancer; brain metastasis; targeted therapy; c-MET/ERBB1 axis; combination therapy;
orthotopic model; spontaneous metastasis; organoids; neratinib; cabozantinib
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1. Introduction
The improved five-year survival rate of ~90% of breast cancer (BC) patients is mainly attributed to
its successful clinical management that includes early screening and effective treatment modalities [1].
However, for BC patients with distant metastasis, the five-year survival rate is ~27%, with a median
survival of 18–24 months [2]. Irrespective of molecular subtypes, BC patients with brain metastasis (BrM)
have the worst cancer-specific survival (CSS). Retrospective analysis of the Surveillance, Epidemiology,
and End Results (SEER) database of BC patients indicates that the ERBB2+ subtype along with
triple-negative BC account for more than 50% of cases of distant metastasis, which preferentially
metastasizes to brain, bone, liver, and lungs [3]. Despite available targeted therapies, metastatic ERBB2+
BC patients have a median survival of ~34 months [3]. The poor therapeutic response towards
targeted therapies in metastatic ERBB2+ BC is attributed in part to clonal evolution in metastatic
cells, their adaptation to the organ-specific microenvironment, and differential drug delivery to the
metastatic niche [4–6]. This is exemplified by the presence of the blood–brain barrier (BBB) in the case
of BrM, which has one of the poorest outcomes among all metastatic BCs [7–9].
The limited success of available therapeutic approaches against metastatic ERBB2+ BC underscores
the need for novel targeted therapies. Recent clinical studies with small molecule inhibitors,
including tyrosine kinase inhibitors, anti-ERBB2 agents, PI3K/Akt/mTOR inhibitors, and CDK4/6
inhibitors, have shown promise in inhibiting proliferation and metastasis in ERBB2+ BC [10–12].
For instance, inhibitors targeting ERBB1 and c-MET receptors that are upregulated during BC
metastasis, are currently being investigated in clinical trials for patients with existing metastasis [13–16].
Neratinib (NER), an irreversible pan-ERBB family inhibitor, has been reported to be efficacious
in metastatic BC patients in combination with capecitabine [17] and paclitaxel [18,19]. Further,
the data from two different clinical trials showed that NER, in combination with either capecitabine
or T-DM1, was effective against brain metastatic ERBB2+ BC, with grade 3 and 4 levels of toxicity,
respectively [14,15]. A recent study in the ERBB2+ spontaneous metastasis model showed that NER
monotherapy (60 mg/kg) inhibited proliferation and distant metastasis in BALB/c mice via inhibition
of ferroptosis [20]. In addition, fluorescent imaging at experimental end-point post-neoadjuvant
treatment with NER showed preventive effects on metastatic progression. Similarly, cabozantinib
(CBZ), an inhibitor of the c-MET receptor, alone or in combination with standard therapies, is being
investigated in ongoing clinical trials for the treatment of patients with metastatic breast and renal cell
carcinomas [13,21,22]. As both ERBB1 and c-MET have been reported to be upregulated in metastatic
ERBB2+ BC and positively correlated with poor survival in ERBB2+ BC patients, these pathways are
considered as potential targets for combination therapies of metastatic BC. However, the effect of
combination therapy, targeting both ERBB1 and c-MET has not been investigated in brain metastatic
ERBB2+ BC.
There are limited preclinical models available to understand underlying mechanism and evaluate
targeted therapies against BrM of ERBB2+ BC. So far, mostly intracardiac and intracarotid injection-based
models have been used to investigate therapeutic approaches against BC BrM [23–25]; however,
both intracardiac and intracarotid models are considered insufficient to represent BC pathogenesis.
In particular, the lack of primary tumors in these models limits the therapeutic evaluation of different
treatment modalities to the metastatic site only, which is not the case in clinical management of
metastatic BC (MBC) patients. In addition, the intracardiac and intracarotid models do not recapitulate
the incidence of spontaneous metastasis and are often considered as models of “forced metastasis”.
Although an orthotopic ERBB2+ BC model for spontaneous metastasis has been reported recently
in BALB/c mouse, it showed 80% incidences of lung and adrenal metastases, respectively, and 50%
and 60% metastasis to bone and brain, respectively [20]. Thus far, there is a lack of clinically relevant
ERBB2+ mouse model that can recapitulate the incidences of distant metastasis like MBC patients.
Particularly, a mouse model demonstrating spontaneous metastasis to the brain is required to evaluate
therapeutic modalities against lethal BrM of BC.
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In the present study, we aimed to evaluate the combined efficacy of ERBB1 and c-MET targeted
therapies in vitro in brain metastatic ERBB2+ cell lines and in an organoid model, and in vivo in a novel
orthotopic model of spontaneous BC metastasis. We observed that FDA approved anti-ErbB1/ErbB2
neratinib (NER) and anti-c-MET cabozantinib (CBZ) inhibited proliferation and metastasis of brain
seeking ERBB2+ SKBrM3 and JIMT-1-BR3 BC cell lines and decreased growth of organoids derived
from huERBB2-Tg mice. To evaluate combination therapy in vivo, we developed a unique ERBB2+
BC orthotopic nude mouse model of spontaneous metastasis that showed primary tumor growth and
clinically relevant distant metastasis to brain, bone, liver, and lung. Combination treatment with NER
and CBZ for 3 weeks was effective in inhibiting the tumor growth and incidence of BrM. Further,
the combination treatment was more effective in preventing brain metastasis with a partial effect on
other metastatic sites. Altogether, treatment with the NER inhibitor alone, and in combination with a
CBZ, is an effective strategy for preventing BrM as observed in the orthotopic model of spontaneous
BC metastasis.
2. Results
2.1. Targeting ERBB1 and c-MET Inhibits Proliferation in Brain-Seeking BC Cell Lines and ERBB2+ Organoids
Previous reports suggest that ERBB1/2 and c-MET pathways play an important role in metastatic
progression of different cancers, including BC [26–29]. We analyzed the expression of ERBB1, ERBB2,
and c-MET receptors in the ERBB2+ brain metastatic BC cell lines SKBrM3 and JIMT-1-BR3. Interestingly,
we observed an increased expression of ERBB1 in both SKBrM3 and trastuzumab-resistant JIMT-1-BR3
cell lines, but relatively reduced expression of ERBB2, as compared to their respective parental cell
lines SKBR3 and JIMT-1 (Figure 1A). In contrast, c-MET expression was upregulated only in SKBrM3
cells as compared to its parental cell line (Figure 1A and Figure S1A). To investigate the efficacy of NER,
we first estimated the inhibitory concentration in SKBrM3 and JIMT-1-BR3 cell lines. The IC50 of NER
for SKBrM3 and JIMT-1-BR3 were estimated as 7.2 µM and 3.3 µM, respectively (Figure S1B). Based on
the inhibitory effect in SKBrM3 cells, we treated all the cell lines with 1 µM NER (below IC20 of SKBrM3
cell line) alone or in combination with different concentrations of CBZ (1–10 µM). The combination
of NER and CBZ significantly inhibited cell proliferation (46.71% ± 4.6%) as compared to NER alone
(10.98 ± 3.2%) and CBZ alone (32.46% ± 8.1%) in SKBrM3 cells (Figure 1B), whereas in the SKBR3 cell
line, the combination treatment inhibited proliferation to a greater extent (68.1% ± 1.3%) compared to
NER alone (36.8 ± 2.8%) and CBZ alone (29.2 ± 5.4%), but the fold-difference in growth inhibition was
lower compared to the SKBrM3 cell line (Figure 1B). These studies suggested that the combination
of NER and CBZ inhibited the growth of SKBrM3 cells in a dose-dependent and synergistic manner.
In contrast, we did not observe a synergistic effect of combination treatment in the JIMT-1-BR3 cell
line (Figure 1C). As JIMT-1-BR3 showed lower expression of the c-MET receptor, we did not pursue it
for evaluation of combination therapy targeting the c-MET/ERBB1 axis. Based on the results in the
proliferation assay, we selected NER (1 µM) and CBZ (5 µM) for further treatments.
Next, we investigated the effect of NER and CBZ on the organoids that were generated from
huERBB2+ transgenic (Tg) mice. Here, we first analyzed the expression of targets pertinent to the
combination treatment. We observed that ERBB1, ERBB2, and c-MET were highly expressed in these
groups. Interestingly, compared to the 84.6% ± 22.2% change in the area of organoids in the control group
(n = 10), the percent change in area for NER treatment was −16.72 ± 22.3% (** p < 0.01); for CBZ treatment
8.9 ± 24.3% (** p < 0.01); and for NER+CBZ treatment −43.06 ± 16.8% (** p < 0.01). Among the treatment
groups, both NER and CBZ decreased proliferation as compared to the untreated control (Figure 1E,F).
However, there was no significant difference in organoid growth between NER and CBZ treatment
groups. Further, the combination treatment with NER and CBZ significantly reduced organoid growth as
compared to the control group (~4-fold reduction; *** p < 0.001) and to single-agent treatments (Figure 1E,F).
These data suggested that the combination of NER and CBZ was effective in the ERBB2+ organoid model
and, therefore, required further investigation in an appropriate in vivo model of metastasis.
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Figure 1. Effect of targeting ERBB1 and c-MET on cell proliferation in brain-seeking breast cancer (BC)
cell lines and huHER2 tumor-derived organoids. (A) Expression of ERBB1, c-MET receptor, and ERBB2
in brain-seeking cell lines SKBrM3 and JIMT-1-BR3 and their respective parental cell lines SKBR3
and JIMT-1 by Western blotting. (B,C) Effect of treatment with NER, cabozantinib (CBZ), or their
combination on proliferation of SKBrM3 and JIMT-1-BR3 cells as compared to their parental cell lines.
The x-axis shows the treatment group for each cell line, whereas the y-axis shows percent cytotoxicity
in different combination treatments in the MTT assay. Concentrations of each treatment are mentioned
on X-axis. (D) Expression of ERBB1 (Alexa488), ERBB2 (Alexa488), and c-MET (Alexa568) receptors
analyzed by immunofluorescence assay. H&E staining in the right panel shows the morphology of the
organoids. The scale bar for IF images was 20 µm, whereas the scale bar for H&E of organoids in right
panel was 100 µm. (E,F) Effect of treatments on organoids. Panel E shows a representative image of
each group including control, NER, CBZ, and their combination (scale bar = 200 µm), whereas panel
F shows quantitative data for the effect of drugs on the growth of huERBB2+ organoids. The area
for each organoid was calculated in µm2 , and the percent change in area of organoids (y-axis) was
plotted for each treatment group (x-axis). Growth was measured in n = 8 organoids for NER and CBZ
treatment groups and n = 10 and n = 11 organoids for control and combination groups, respectively.
The statistical significance among different groups was calculated by one-way ANOVA with * p < 0.01;
** p < 0.001; and *** p < 0.0001; NS = No significance.
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2.2. Effect of NER and CBZ Treatment on Migration of Brain Seeking Cells
We performed a Boyden chamber migration assay to evaluate the effect of combination therapy
on cell migration. Interestingly, we observed that NER (1 µM) and CBZ (5 µM) concentrations each
inhibited in vitro cell migration of SKBrM3 as well as SKBR3 cell lines (Figure 2A). In the SKBrM3 cell
line, NER and CBZ alone inhibited migration by 32.3 ± 2.9% and 29.2 ± 4%, respectively, compared to
the untreated control group (Figure 2B). The effect was even greater with a combination of NER and
CBZ in the SKBrM3 cell line (63.25 ± 7.6%), suggesting that targeting the ERBB1 and c-MET receptors
inhibits cell motility in the SKBrM3 cell line. In contrast, CBZ alone significantly reduced the migration
of JIMT-1, but not JIMT-1-BR3 cells (Figure 2A), possibly due to reduced expression of c-MET in the
latter cell line. These studies suggested that the c-MET receptor might not be a potential target in
JIMT-1-BR3 cells. However, NER treatment reduced the migration of JIMT-1-BR3 cells by 76 ± 1.6%
(Figure 2B) as compared to the untreated control group. The quantitative analysis showed that more
SKBrM3 cells migrated through the 0.8 µm barrier as compared to the parental cell line, possibly due
to their higher metastatic potential (Figure 2B).

Figure 2. Effect of combination treatment on downstream signaling and in vitro metastatic behavior.
(A,B) Effect of combination treatment on in vitro migratory potential of SKBrM3 and JIMT-1-BR3 cell
lines. Brain-seeking BC cell lines SKBrM3 and JIMT-1-BR3 and their respective parental cell lines SKBR3
and JIMT-1 were treated with NER (1 µM), CBZ (5 µM), or their combination. Cells that migrated through
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the Boyden chamber were stained (A) and quantified (B) to analyze the effect of treatment on cell
migration; scale bar = 1000 µm. (C,D) Cell lysates collected after 48 h of treatment with NER (1 µM) and
CBZ (5 µM) were analyzed by Western blotting. Expression levels of target molecules pERBB1/ERBB1,
pERBB2/ERBB2, and pc-MET/c-MET were analyzed along with downstream pERK/ERK and pAKT/AKT
signaling molecules in SKBrM3 cells and parental cell line SKBR3 (C), and in JIMT-1-BR3 and parental
cell line JIMT1 (D). Beta-actin expression was used as a loading control for each cell line. (E) Schematic
representation of trans-endothelial migration (TEM) assay. (F) Trans-endothelial migration was
quantified in SKBrM3 cells treated with NER and CBZ alone, or their combination. (G) Micrograph
showing CBZ and NER treated SKBrM3 cells transmigrated in trans-endothelial assay; scale bar = 400
µm. Experiments were performed in triplicate, and a paired t-test was used to calculate the statistical
significance (**** p < 0.0001; *** p < 0.005; ** p < 0.01; * p < 0.05, ns = No significance).

2.3. Effect of NER and CBZ on Downstream Signaling
The synergistic regulation of signaling mediated by ERBB1 and c-MET receptors is important
in the regulation of cancer progression, metastasis, and drug resistance [16,28,30]. The downstream
protein kinase B (PKB/Akt) and extracellular signal-regulated kinase (ERK) are co-regulated by both
ERBB1 and c-MET receptors [31]. Therefore, we analyzed the effect of NER (1 µM) and CBZ (5 µM)
for 48 h on the expression of ERBB1 and c-MET receptors, and assessed the effect of combination
treatment on activation of AKT and ERK molecules in SKBrM3, JIMT-1-BR3, and their respective
parental cell lines. Interestingly, NER, as a single agent, as well as in combination with CBZ, modulated
pERBB2 (Tyr1248), pERBB1 (Tyr1068), and its downstream pAKT (Ser473) and pERK (Thr982) signaling
(Figure 2C,D). Particularly in metastatic SKBrM3 and JIMT-1-BR3 cell lines, 1 µM NER treatment
reduced downstream pERK and pAKT expression, suggesting that NER treatment alone is efficacious
in inhibiting downstream signaling. In contrast, CBZ at 5 µM had no effect on ERK and AKT
phosphorylation. Furthermore, a combination with NER (1 µM) and CBZ (5 µM) reduced pERK
signaling with a partial effect on pAKT signaling (Figure 2C,D), suggesting that downstream pERK
signaling is critical in the metastatic SKBrM3 cell line. Further, we observed a similar response
with NER alone or NER in combination with CBZ on the JIMT-1-BR3 cell line that expressed a low
endogenous level of c-MET, suggesting specificity of CBZ with c-MET expression.
2.4. Effect of NER and CBZ on In Vitro Trans-Endothelial Migration
The BBB is selectively permeable under normal physiological conditions. However, the pathological
cues, including brain metastasis, render the loss of BBB integrity, which transforms the intact BBB into
the blood–tumor barrier (BTB) and alters the permeability for therapeutic agents [32–34]. As the SKBrM3
cell line expresses high c-MET and ERBB1 receptors, and the combination treatment of NER and CBZ
predominantly downregulated the pERK pathway in this cell line, we examined the effect of treatment
on the migration of SKBrM3 cell line in vitro that mimics the human BBB to some extent (Figure 2E).
We also observed a greater impact of combination treatment in the trans-endothelial migration (TEM)
assay. Interestingly, as compared to the control group, NER and CBZ alone inhibited the TEM 66.16%
± 3.18 and 55.10% ± 2.17, respectively, whereas inhibition of migration was significantly greater in the
combination treatment (92.79% ± 0.89; Figure 2F). Further, to visualize the effect of combination therapy
on TEM of SKBrM3 cells, we presented the micrograph data, which showed that the combination
treatment with NER and CBZ elicited a more profound effect as compared to control and single
agent treatments (Figure 2G). In addition, the efficacy of combination treatment of NER and CBZ was
significantly higher than single treatment groups, suggesting that targeting the c-MET/ERBB1 axis
could be a potential therapeutic strategy to prevent brain metastasis.
2.5. Characterization of the Orthotopic Model of Spontaneous BC Metastasis
Animal models developing distant metastasis either due to spontaneous progression of BC or by
orthotopic implantation in mammary fat-pads are useful to understand the molecular mechanisms
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regulating various steps of metastatic progression and for evaluating the anti-tumor and anti-metastatic
activity of targeted therapies. To develop a BC orthotopic model of spontaneous metastasis, we selected
SKBrM3 cells, as these cells express high endogenous levels of c-MET and ERBB1 and showed an
adequate response in combination in vitro compared to other cell lines. We first enriched SKBrM3
cells using the Boyden chamber as demonstrated in the schematic (Figure 3A). The enriched SKBrM3
cells (SKBrM3+ hereafter) exhibiting high vimentin and ZEB1 expression (Figure 3B) were used
for orthotopic injection in the fat pad of the fourth mammary gland of female nude mice (n = 6).
We observed a progressive tumor growth kinetics and after 6 weeks, we euthanized tumor-bearing
mice to record tumor weights and incidences of metastasis. The average tumor weight was found to
be 1.43 ± 0.32 g. Representative images from bioluminescence imaging (BLI) of orthotopic tumors and
pictures of isolated tumors are shown with in Figure 3C. Subsequently, we assessed the composition
of the tumor microenvironment in SKBrM3+ orthotopic tumors. The IF staining suggested that the
tumors were highly positive for α-SMA (fibroblasts), CD31 (blood vessels), and F4/80 (macrophages),
which are considered as major cellular constituents of the tumor microenvironment and play an
instrumental role in metastatic progression [35–38] (Figure 3D). Next, we analyzed the expression of
target molecules in the tumor sections derived from the mammary fat pads of implanted mice.

Figure 3. Development and characterization of an orthotopic mouse model for BC. (A) Schematic to show
in vitro enrichment of migration potential in SKBrM3 cells by sequential passaging through a Boyden
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chamber (SKBrM3+ or BrM3+ ), as mentioned in Material and Methods. (B) The expression levels of
pERBB1/ERBB1, pERBB2/ERBB2, pc-MET/c-MET, and the metastasis markers vimentin and ZEB1 were
analyzed in SKBrM3+ cells using immunoblotting. (C,D) Characterization of an orthotopic model of
BC metastasis in athymic nude mice. (C) Representative bioluminescence imaging (BLI) images and
pictures of harvested orthotopic tumors and their histological and proliferation analysis stained by H&E
(upper left) and Ki-67 (lower left) (scale bar = 20 µm). (D) IF staining of tumor sections for the analysis of
macrophages (F4/80), blood vessels (CD31), and fibroblasts (α-SMA) (E) Expression of pERBB1, pERBB2,
and pc-MET in SKBrM3+ tumors derived from nude mice (scale bar = 1000 µm). Images were magnified
(lower panel) to highlight the tumor sections with positive staining. (F) Representative BLI images of
isolated organs and percent incidences of distant metastasis in the SKBrM3+ BC orthotopic model.

Interestingly, we observed high expression of pERBB1, pERBB2, and pc-MET in SKBrM3+ tumor
sections in Immunohistochemistry (IHC) analysis (Figure 3E). Furthermore, we isolated the organs
and performed BLI to analyze incidences of metastasis in different organs. Interestingly, mice bearing
orthotopic tumors exhibited extensive distant metastasis to the bone, brain, liver, and lung, which are
the major organs of metastasis in the ERBB2+ BC subtype (Figure 3F). Representative images from BLI
are shown for each organ along with the total incidences of metastasis (Figure 3F). Further, we observed
that SKBrM3+ cells exhibited high incidences of brain metastasis, and we found five mice out of six to
be positive in BLI. The organ-specific metastatic behavior of SKBrM3+ cells might be a cumulative result
of sequential in vitro enrichment, the injection site, and/or influence of the tumor microenvironment
on disseminated cells.
2.6. NER and CBZ Treatment Decreases Tumor Growth and Prevents Distant Metastasis
As the upregulated ERBB1 and c-MET pathways contribute to BC progression and distant
metastasis [26–28], we investigated the ability of NER and CBZ to prevent primary tumor growth
and metastasis in the orthotopic model of spontaneous metastasis (n = 5). Based on previous
studies, we considered lower doses of NER and CBZ (20 mg/kg body weight each) to investigate
combined efficacy in vivo [39,40]. As mentioned in the experimental plan, we administered NER
and CBZ orally five days a week for three weeks (Figure 4A). Following three weeks of treatment,
we analyzed the effect of combination therapy on tumor growth and metastasis. Interestingly, both
NER (20 mg/kg/body weight) and CBZ (20 mg/kg/body weight) decreased the average tumor volume
by 85.7% and 67.4%, respectively, as compared to the control group (Figure 4B). The combination
treatment further decreased the average tumor volume by 90.2% of the control group (Figure 4B),
which was also observed in BLI before euthanization of mice at experimental endpoint (Figure 4C),
and in the images of isolated tumors (Figure 4D). This data was further substantiated by analysis of
isolated tumors from each group, where we observed that the average tumor weights were significantly
decreased in each treatment group including NER (70.8% ± 10.45%; ** p < 0.01), CBZ (58.25% ± 14.2%;
* p < 0.05), and combination (75.82% ± 18.74%; ** p < 0.01) as compared to the control group (Figure 4E).
Further immunohistochemical analysis of the primary tumors demonstrated significantly lower Ki-67+
cells in the combination treatment groups as compared to the control group and single treatment
groups (Figure 4F,G). Overall, the combination treatment of NER and CBZ significantly reduced the
tumor growth, as compared to CBZ alone and untreated control group.
We further analyzed the effect of combination treatment with NER and CBZ on incidences of
metastasis by a using small animal imaging system. The BLI analysis of isolated organs suggested that
the combination of NER and CBZ predominantly showed a preventive effect on the incidences in BrM
(Figure 5A,B). We found that 80% of mice did not show incidences of BrM after the treatment with
combination treatment. In contrast, the combination of NER and CBZ showed a preventive effect to a
lesser extent in the case of bone metastasis, but we observed reduced metastatic burden in bone post
treatment, as compared to the control group (Figure 5A,B).
As a single agent, NER prevented BrM in three out of the five mice, whereas it had a limited effect
on bone metastasis, and only one mouse was observed with no metastasis (Figure 5A,B). In contrast,
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CBZ as a single agent was more effective in decreasing BrM than lung, liver, and bone metastasis
(Figure 5A,B). Overall, the data suggested that the combination of NER and CBZ effectively prevented
metastasis to the brain with a partial effect on lung, bone, and liver metastasis. The differential response
to combination therapy might be due to differential metastatic burden or due to poor response towards
the therapy at different metastatic sites.

Figure 4. In vivo efficacy of combination treatment against tumor growth in the orthotopic model of
metastasis. (A) Experimental plan for analyzing the efficacy of NER, CBZ, and their combination in
an athymic mouse model of metastasis. (B) Tumor growth kinetics (n = 5 mice/group) after 3 weeks
of therapy in different groups including NER (20 mg/kg/mouse), CBZ (20 mg/kg/mouse), and their
combination. (C) BLI of mice from each control and treatment groups at the experimental endpoint
was performed using the small animal imaging platform. Following live animal imaging, mice were
sacrificed, and primary tumors were harvested as photographed (D), and weighed for each treatment
group (E). (F,G) SKBrM3+ tumor sections were stained for Ki-67 expression in different treatment groups
to analyze the effect of combination treatment on the percent proliferating cells (Scale bar = 1000 µm:
upper right panel in each image showed magnified image). Statistical significance was calculated on
GraphPad software using one-way ANOVA to compare tumor growth in different treatment groups
with vehicle control (* p < 0.05; ** p < 0.01, *** p < 0.001; NS = No significance).
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Figure 5. Effect of targeting the ERBB-c-MET axis on distant metastasis. (A) Post-therapy IVIS imaging
of isolated metastatic organs including brain, bone, lung, and liver. Organs were harvested 3 weeks after
the therapy with NER, CBZ, and their combination. (B) Stacked bar-graph to show the quantification
of organ-specific metastasis using BLI, where the x-axis shows the percent incidences for metastasis in
each organ including brain (blue), bone (orange), liver (gray), and lung (yellow), and the y-axis shows
different treatment groups including control, NER, CBZ, and their combination.

3. Discussion
Targeted therapies, particularly the anti-ERBB2 antibody trastuzumab (Herceptin) and its
derivatives, alone or in combination, have greatly improved survival in ERBB2+ BC patients [41–43].
In contrast, there are limited targeted therapies available with modest therapeutic responses to target
distant metastasis in ERBB2+ BC patients [3,44,45]. The optimization of targeted therapies against
metastatic ERBB2+ BC is challenging for several reasons, including molecular and metabolic adaptations
in metastasizing cells, refractive organ-specific microenvironments, and lack of preclinical models to
evaluate therapeutic targets [9,46–48]. In this study, we reported an orthotopic model of spontaneous
ERBB2+ BC BrM that can be used to evaluate therapeutic approaches targeting both the primary tumor
and distant metastases together, suggesting its high clinical relevance. Previously, an orthotopic mouse
model of BrM using triple-negative cell lines MDA-MB-231 and 4T1 have been reported in NSG and
BALB/c mice, respectively, which are suitable for therapeutic modalities against TNBC [49–52]. In the
ERBB2+ BC subtype, both intracardiac and intracarotid models have been used for the evaluation of
therapeutic modalities against BC BrM [24,25,53]. However, neither of these models are enough to
understand the mechanisms of BC progression and metastasis, nor can they be used to test preventative
therapies in BC. Recently, an ERBB2+ orthotopic model of spontaneous metastasis has been reported in
BALB/c mouse [20]. However, the incidences of metastasis are more in lungs (~80%) as compared to
bone (50%) and brain (60%). Conversely, the orthotopic nude mouse model described in this study is,
physiologically, more relevant compared to intracardiac and intracarotid models and ideally suitable
for the evaluation of therapeutic modalities against BC metastasis due to the presence of both matched
primary and metastatic tumors. In addition, the SKBrM3+ orthotopic model exhibited consistently high
incidences of metastasis to bone and brain, which recapitulates the clinical metastatic burden observed
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in metastatic BC patients [3]. For the assessment of metastasis in small animals like mouse models,
BLI is the most commonly used method that is based on the luciferase activity of engineered metastatic
cell lines [54,55]. Assessment of various organs derived from LUC+SKBrM3+ cell line implanted mice
by BLI helped us to clearly identify the metastatic burden in different treatment groups. Therefore,
BLI imaging of intact and freshly harvested tissues is an excellent approach to analyze incidences of
metastasis using highly sensitive luciferin drugs and could be used to analyze metastases. However,
further evaluation of molecular markers, radiological imaging, and histological analysis could be used
for deeper insight of metastatic progression and associated pathways.
In line with previous reports that showed co-amplification of c-MET and ERBB pathways and
their role in metastatic BC [24,56,57], we observed the higher expression of c-MET and ERBB1 receptors
in ERBB2+ brain-seeking SKBrM3 cells as compared to its parental cell line, and in organoids derived
from ERBB2-Tg mouse. As both the brain metastatic cell lines SKBrM3 and JIMT-1-BR3 showed altered
molecular expression as compared to their parental cell line, our results support the existing notion
that molecular expression is influenced during the gain of metastatic traits and in response to the
microenvironment at metastatic sites [5,7,58]. For example, a recent multicenter study analyzed the
genomic profile and subtype switching in BC patients who were diagnosed with BrM. Interestingly,
there was differential genomic profiles in case of BrM as compared to their respective primary tumors
and more than 20% patients showed subtype switching, including ERBB2+ patients [59]. In the
case of BC, the amplification of ERBB receptors correlates with disease aggressiveness and distant
metastasis [56,57]. Particularly, ERBB1 overexpression or its co-amplification with other ERBB receptors
has been reported to favor distant metastasis [57]. Similarly, c-MET overexpression has been reported to
contribute to BC metastasis, particularly to the brain. Previously, gene set enrichment analysis (GSEA)
of a large cohort of BC patients (n = 710), 47 with BrM, showed a highly enriched c-MET-pathway in BrM
patients [24]. In addition, the upregulation of c-MET is associated with BrM, not to the bone metastasis,
and the knockdown of c-MET in brain-seeking cells has been reported to significantly increase BrM-free
survival in vivo [24]. Interestingly, activation of c-MET was shown to induce high IL-1β secretion
leading to an IL-8 and CXCL1 dependent feed-forward loop, creating a favorable environment for
BrM. Further, the co-amplification and cross-talk between c-MET and ERBB1 pathways have been
reported in different malignancies, including BC that regulates tumor progression, distant metastasis,
and therapeutic resistance [29,30,60,61]. Previously, it has been reported that targeting both ERBB1
and c-MET receptors sensitizes cancer cells to targeted therapy [30]. Moreover, c-MET amplification
has been reported to mediate resistance to ERBB1 inhibitors [61]. In another study, tissue samples
from 825 BC patients were analyzed to correlate the expression of upregulated proteins. The study
highlighted that ERBB1 overexpression correlated with high p-c-MET expression [62], substantiating
our hypothesis that the co-targeting of ERBB1 and c-MET could be an important therapeutic strategy
in the treatment of BC progression and metastasis.
Our results in cell lines and organoids derived from the huERBB2-Tg mouse model provide
evidence that combined inhibition of the ERBB1/ERBB2, and c-MET pathways could synergistically
inhibit proliferation and metastasis in BC. Due to their intact tumor architecture, organoids are
considered as a robust model for therapeutic drug testing in solid tumors, including BC [63–66].
The therapeutic effect of NER and CBZ in ERBB2+ organoids was further substantiated by in vivo
findings in the orthotopic model of spontaneous metastasis. Both NER and CBZ have been reported
to cross the BBB and, therefore, could be used to target BrM in our orthotopic model of spontaneous
metastasis. Our results showed that the combination of NER and CBZ not only effectively decreased
tumor volume but also prevented the incidences of metastasis in this BC orthotopic model. Previously,
NER monotherapy in neoadjuvant settings has been shown to inhibit tumor growth and metastasis in
the ERBB2+ orthotopic model of spontaneous metastasis [20]. However, the spontaneous metastasis
was observed more in adrenal and lungs rather than bone and brain, which are the most common sites
of metastasis in ERBB2+ BC patients. These studies suggest that interpretation of the therapeutic effect
of NER monotherapy on distant metastasis might be difficult in the BALB/c model. In contrast, like our
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findings, the preventive effect of neoadjuvant NER therapy has been reported predominantly in case
of BrM in the BALB/c model. However, the differential therapeutic response in different metastatic
sites might be due to the altered molecular profile of metastatic cells and due to organ-specific
microenvironments at different metastatic sites. Previous reports have provided solid evidence that
cells metastasizing to different organs have different genetic and molecular profiles, leading to subtype
switching; therefore, metastatic cells differ in their organotropism as well as their response to targeted
therapies [7,58,59,67]. In addition, neoadjuvant NER therapy was reported less efficacious in preventing
lung and liver metastasis, as compared to brain metastasis in the BALB/c model [20].
Mechanistically, our findings show that combination therapy profoundly downregulated the
MAPK/ERK pathway, which is downstream to c-MET and ERBB1 pathways. Previous studies have
highlighted the MAPK/ERK pathway as a key mediator of proliferation and metastasis in metastatic
BC that together with AKT/mTOR and STAT3 plays an essential role in progression of BrM [53,68,69].
A recent study showed that NER monotherapy inhibits proliferation of ERBB2+ BC via inhibition of
ferroptosis [20]. In addition, other pathways, including PI3K, PARP, CDK4/6, FAK, etc., have been
reported to play essential roles in BrM progression [70]. Therefore, combination therapies targeting
multiple pathways might be an important strategy in the management of BrM in BC. We have
summarized the treatment strategy in the graphical abstract (Figure 6). Although a three-week
low dose regimen of NER and CBZ combination therapy decreased tumor growth and incidences
of metastasis in our orthotopic model of spontaneous BC metastasis, we assume that treatment
with the maximum tolerated dose in combination treatment would provide more profound in vivo
efficacy. In addition, the orthotopic model of spontaneous metastasis will be a useful reagent to
investigate underlying mechanisms involved in metastatic progression of BC and for evaluation of
novel therapeutic approaches against BC metastasis.

Figure 6. Schematic diagram showing targeted inhibition of the ERBB-c-MET axis to prevent BC
metastasis in an orthotopic ERBB2+ mouse model. (A) In vitro enrichment of the SKBrM3 cell line
using a Boyden chamber. (B) Orthotopic implantation of SKBrM3+ cells in fourth mammary fat pads of
female nude mice. (C) Incidences of metastasis in distant organs including brain, bone, liver, and lung.
(D) Combination treatment of NER and CBZ after 3 weeks of implantation. (E,F) Effect of combination
therapy on primary tumor growth and metastasis.
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4. Methods
4.1. Animal Use and Ethics
All animal work was performed as per the protocols (#17-019-04 FC) approved by the Institutional
Animal Care and Use Committee (IACUC) at the University of Nebraska Medical Center (UNMC).
The animals were kept in a specific pathogen-free animal care facility at UNMC.
4.2. Cell Lines and Reagents
The SKBR3 cell line was procured from ATCC, and its metastatic derivative SKBrM3 was kindly
gifted by Dr. Watabe from the Wake Forest School of Medicine, Winston Salem, North Carolina.
Dr. Steeg from the National Cancer Institute kindly gifted us the JIMT-1-BR3 cell line, and the JIMT-1
cell line was obtained from Dr. Hamid Band at UNMC and maintained as described previously [71].
The drugs neratinib (Cat. No. S2150) and cabozantinib (Cat. No. S1119) used in the study were
purchased from Selleckchem.
4.3. Proliferation Assay
Cell proliferation assays were performed, as described previously [72–74]. Briefly, five thousand
cells per well were seeded in a 96-well plate in 10% FBS containing RPMI media for SKBR3
and SKBrM3 cell lines and in 10% FBS containing DMEM media for JIMT-1 and JIMT-1-BR3 cell
lines. The next day, cells were starved in 2% FBS medium for 2 h prior to the drug treatments.
After 2 h of serum starvation, cancer cells were treated with different concentrations of drugs,
as mentioned in the Results Section. After incubation of cells at 37 ◦ C for 48 h, we added 10 µL of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT, 5 mg/mL, Sigma, St. Louis, MO,
USA) to each well. After adding MTT, plates were then incubated at 37 ◦ C for 4 h. Absorbance was
measured at 570 nm using a microplate reader (Spectramax 190 Microplate Reader, Molecular Devices,
LLC, USA).
4.4. Migration Assay
We performed the cell migration assay as published previously [75]; 1 × 106 cells were seeded in
6-well plates in their respective media for 48 h in the presence of NER (1 µM) and CBZ (5 µM), and their
combination. The drug-treated cells were trypsinized and seeded at a density of 5 × 105 cells/well in
a 6-well Boyden chamber in serum free media. In the lower chamber of 6-well plates, 10% serum
containing media was added to demonstrate the in vitro effect of the above treatments on migration of
brain metastasis and their respective primary cell lines. After 16 h, migrated cells on the opposite side
of the trans-well were fixed in 100% methanol, stained with 0.1% crystal violet, imaged, and counted
using an EVOS® FL auto imaging system microscope CA, USA).
4.5. Trans-Endothelial Migration
The trans-endothelial migration (TEM) was performed as described earlier [76]. Briefly, we seeded
5 × 105 brain endothelial cells on the upper outer surface of the gelatin coated trans-well for 24 h. In the
lower chamber, 5 × 105 human astrocytes were cultured for 24 h. the next day, drug treated brain tropic
SKBrM3 cells were seeded onto the top of endothelial cells in a trans-well insert. All the three cells
types were incubated for the next 16 h in co-culture conditions, and transmigrated cells were counted
by fixing cells in 100% methanol and stained with 0.1% crystal violet. Transmigrated cells were imaged
and counted using an EVOS® FL auto imaging system microscope (Life Technologies, CA, USA).
4.6. Immunohistochemistry
Immunohistochemistry (IHC) was performed on tumor tissues as described earlier [77]. Briefly,
tissue sections were kept overnight at 58 ◦ C and followed by xylene wash and alcohol gradient-based
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hydration. Citrate buffer (pH = 6) was used for antigen retrieval, followed by peroxidase quenching
using 0.3% H2 O2 in methanol. Following 3 washes in water, tissues were blocked in 2.5% horse serum
and incubated overnight in primary antibody cocktail, ERBB1 (D38B1; 1:400), ERBB2 (Cat. No. 2242;
1:200), and c-MET (Cat. No. 4560; 1:200, purchased from Cell Signaling technologies, Beverly, MA,
USA. The next day, after washing off unbound primary antibodies, an HRP-conjugated antibody
cocktail (ImmPress Universal antibody kit, Vector Laboratories, Burlingame, CA, USA) was used
for 30 min at RT and developed using 3-3’ diaminobenzidine solution (DAB substrate kit (SK-400),
Vector Laboratories, Burlingame, CA, USA. Following counterstain with hematoxylin, the slides were
dehydrated in an alcohol gradient from 25% to 100%, followed by 3 xylene washes. After that, air-dried
tissue sections were mounted using paramount media (Fisher Scientific, PA, USA) and visualized
under the microscope.
4.7. Immunofluorescence
For immunofluorescence in cell lines and tissues, we followed previously published protocol with
slight modifications [78,79]. Briefly, the coverslip adhered cells were fixed in 4% paraformaldehyde
for 15 min at RT, washed in 0.1% glycine, and permeablized in 0.1% TritonX100 for 10 min at
RT. After washing in PBS, cells were blocked in 10% normal goat serum for 2 h, followed by
incubation in primary antibodies specific to ERBB1 (D38B1; 1:400), ERBB2 (Cat. No. 2242; 1:200),
and c-MET (Cat. No. 4560; 1:200) for O/N incubation in a humidified chamber. The next day, slides were
washed 3 times in PBS containing 0.1% Tween-20 (PBS-T) and incubated for 45 min at RT with
fluorophore-conjugated secondary antibodies. Following four washes in PBS-T, the cells or tissue
sections were mounted in DAPI-containing mounting media and then visualized under the microscope.
4.8. Western Blotting
Immunoblotting was performed as described previously [80]. Briefly, 40 µg of each cell lysate was
separated by 10% SDS–PAGE and then transferred to a polyvinylidene fluoride (PVDF) membrane
(Millipore, USA). The membranes were blocked in 5% skimmed milk for 1 h and incubated overnight
at 4 ◦ C with primary antibodies against pERBB1 (D7A5:1:1000), CST; ERBB1 (D38B1; 1:1000), CST;
p-c-MET (D26; 1:1000), CST; c-MET (4560; 1:1000), CST; pERBB2 (2247s; 1:1000), CST; ERBB2 (2242;
1:1000), CST; pERK (9102; 1:1000), CST; ERK (9101; 1:1000), CST; pAKT (9271; 1:1000), CST; AKT (4691;
1:1000), CST. All these antibodies were purchased from Cell Signaling technologies, Beverly, MA, USA,
unless, mentioned specifically. Following washes with PBST, the membranes were incubation with
HRP-conjugated anti-rabbit or anti-mouse IgG (1:3000; Santa Cruz Biotechnology, Dallas, Texas, USA)
for 1 h. The proteins were visualized using ECL-plus reagents (Amersham Biosciences Corp., USA).
4.9. Organoid Culture and Treatment Assay
Tumor tissues were enzymatically digested and processed as described previously [81]. Briefly,
freshly harvested tissues were digested with 0.012% (w/v) collagenase XI (Sigma) and 0.012% (w/v)
dispase (GIBCO, MD, USA) in DMEM media containing 1% FBS (GIBCO) and embedded in growth
factor reduced Matrigel (BD Biosciences, San Jose, CA, USA). The organoids were cultured in
AdDMEM/F12 (GIBCO) media supplemented with 0.1% insulin–transferrin–selenium (ITS-G) (100×)
(Gibco™, MD, USA), FGF10, and FGF 2 (PreproTech, Cranbury, NJ, USA), in a 5% CO2 incubator at
37 ◦ C. On the 5th day, the tumor organoids were treated with drugs, and changes in the size and
morphology were followed consecutively for 7 days. The bright-field images were acquired on an
EVOS® FL auto imaging system microscope (Life Technologies, CA, USA), followed by quantification
of the change in area of selected organoids.
4.10. Orthotopic Mouse Model
SKBrM3 cells were harvested at 70–80% confluency using 0.025% trypsin and seeded at
5 × 105 -cells/well density in the upper chamber of a 0.8-µm pore size trans-well inserted in 6-well
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plates containing 1.5 mL media. The migrated cells were collected from the wells and then subjected
to two more cycles of enrichment. After analyzing the luciferase activity, 1 × 106 enriched SKBrM3+
(or BrM3+ ) cells in 100 µL of PBS were orthotopically implanted in the fourth mammary fat pad of 6to 8-week-old female nude mice. Tumor growth was followed by caliper-based measurements, as well
as by imaging the mice on a small-animal in vivo imaging system (IVIS) on a weekly basis.
4.11. Drug Treatment and Animal Imaging
We evaluated the effect of oral doses of NER (20 mg/kg/mouse) alone, CBZ (20 mg/kg/mouse)
alone, or their combination in our orthotopic model of ERBB2+ spontaneous BC metastasis using 6- to
8-week-old female nude mice. The tumor volume and body weight of each mouse were measured
every 4th or 5th day. Post-treatment, the mice were first injected intraperitoneally (IP) with 15 mg/kg
bodyweight of D-luciferin (Cat No. 122799, Perkin Elmer, Akron, OH, USA), and imaging was
performed using small animal IVIS to analyze the effect on tumor growth. Further, the mice were
sacrificed as per the IACUC guidelines and organs associated with BC distant metastasis including
bone (from hind limbs), brain, liver, and lungs were harvested for single organ imaging to investigate
the micrometastases. Following imaging and weighing of the tumors, the organs were preserved in
10% buffered formalin for fixation and further analysis.
4.12. Statistical Analysis
The statistical analysis was performed using Student’s t-test (* p < 0.05; ** p < 0.01; *** p < 0.001).
For comparison among the independent treatment groups, we used a one-way analysis of variance
(ANOVA) with a cutoff of p < 0.05. Tukey’s multiple comparison test was performed to analyze the
statistical significance for difference in tumor weights as well as tumor volumes among different
treatment groups using two-way ANOVA with * p < 0.05; ** p < 0.01; *** p < 0.001; and **** p < 0.0001.
5. Conclusions
We report in this paper an orthotopic mouse model for spontaneous BC metastasis that shows high
incidences of BrM along with other clinically relevant distant organ metastases, including bone, liver,
and lungs. Next, in concordance with high expression of ERBB1 and c-MET receptors, the combination
treatment of NER and CBZ showed significant anti-proliferative effects in brain seeking cell line
SKBrM3 and ERBB2+ organoids and elicited a profound inhibitory effect on cell migration in vitro.
Our in vitro data was further substantiated by an in vivo preventive treatment approach where the
combination treatment with NER and CBZ significantly reduced the primary tumor burden and
demonstrated preventive effects on metastatic progression to the brain in an orthotopic model of
spontaneous BC metastasis (Figure 6). Overall, the combination of NER and CBZ could effectively
inhibit BrM and targeting the c-MET/ERBB1 axis could be a unique strategy for preventing ERBB2+
BC BrM.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/10/2838/s1,
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vimentin, and ZEB1. Corresponding β-actin blot was shown as loading control.
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